Cargando…

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide

Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales: TADA, YOSHITAKA, YOSHIKAWA, TOSHIAKI, SHIMOMURA, MANAMI, SAWADA, YU, SAKAI, MAYUKO, SHIRAKAWA, HIROFUMI, NOBUOKA, DAISUKE, NAKATSURA, TETSUYA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 201
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829797/
https://www.ncbi.nlm.nih.gov/pubmed/23903757
http://dx.doi.org/ 10.3892/ijo.2013.2044
_version_ 1782291390856691712
author TADA, YOSHITAKA
YOSHIKAWA, TOSHIAKI
SHIMOMURA, MANAMI
SAWADA, YU
SAKAI, MAYUKO
SHIRAKAWA, HIROFUMI
NOBUOKA, DAISUKE
NAKATSURA, TETSUYA
author_facet TADA, YOSHITAKA
YOSHIKAWA, TOSHIAKI
SHIMOMURA, MANAMI
SAWADA, YU
SAKAI, MAYUKO
SHIRAKAWA, HIROFUMI
NOBUOKA, DAISUKE
NAKATSURA, TETSUYA
author_sort TADA, YOSHITAKA
collection PubMed
description Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical efficacy. Moreover, we proposed that a peptide-specific CTL response is a predictive marker of overall survival in patients with HCC who receive peptide vaccination. In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A ( * ) 02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. Established CTL clones were analyzed using the IFN-γ ELISPOT assay and a cytotoxicity assay. GPC3 peptide-specific CTL clones were established successfully from the PBMCs of the patient. One CTL clone showed cytotoxicity against cancer cell lines that expressed endogenously the GPC3 peptide. The results suggest that CTLs have high avidity, and that natural antigen-specific killing activity against tumor cells can be induced in a patient with HCC who shows a clinical response to vaccination with the GPC3 ( 144–152 ) peptide.
format Online
Article
Text
id pubmed-3829797
institution National Center for Biotechnology Information
language English
publishDate 201
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-38297972013-11-18 Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide TADA, YOSHITAKA YOSHIKAWA, TOSHIAKI SHIMOMURA, MANAMI SAWADA, YU SAKAI, MAYUKO SHIRAKAWA, HIROFUMI NOBUOKA, DAISUKE NAKATSURA, TETSUYA Int J Oncol Articles Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical efficacy. Moreover, we proposed that a peptide-specific CTL response is a predictive marker of overall survival in patients with HCC who receive peptide vaccination. In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A ( * ) 02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. Established CTL clones were analyzed using the IFN-γ ELISPOT assay and a cytotoxicity assay. GPC3 peptide-specific CTL clones were established successfully from the PBMCs of the patient. One CTL clone showed cytotoxicity against cancer cell lines that expressed endogenously the GPC3 peptide. The results suggest that CTLs have high avidity, and that natural antigen-specific killing activity against tumor cells can be induced in a patient with HCC who shows a clinical response to vaccination with the GPC3 ( 144–152 ) peptide. D.A. Spandidos 2013 -07- 31 /pmc/articles/PMC3829797/ /pubmed/23903757 http://dx.doi.org/ 10.3892/ijo.2013.2044 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
TADA, YOSHITAKA
YOSHIKAWA, TOSHIAKI
SHIMOMURA, MANAMI
SAWADA, YU
SAKAI, MAYUKO
SHIRAKAWA, HIROFUMI
NOBUOKA, DAISUKE
NAKATSURA, TETSUYA
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title_full Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title_fullStr Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title_full_unstemmed Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title_short Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
title_sort analysis of cytotoxic t lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829797/
https://www.ncbi.nlm.nih.gov/pubmed/23903757
http://dx.doi.org/ 10.3892/ijo.2013.2044
work_keys_str_mv AT tadayoshitaka analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT yoshikawatoshiaki analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT shimomuramanami analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT sawadayu analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT sakaimayuko analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT shirakawahirofumi analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT nobuokadaisuke analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide
AT nakatsuratetsuya analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide